BioAge Doses First Patient in Phase 2 Trial of NLRP3 Inhibitor for Cardiovascular Risk
Event summary
- BioAge Labs dosed the first participant in its Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inhibitor, for patients with elevated cardiovascular risk.
- The trial will evaluate three once-daily oral doses of BGE-102 in approximately 160 adults with obesity and elevated systemic inflammation.
- Primary endpoint is percent change in high-sensitivity C-reactive protein (hsCRP), with topline data expected in the second half of 2026.
- BGE-102 previously showed potential best-in-class hsCRP reductions and was well tolerated in Phase 1 trials.
- BioAge plans to initiate a Phase 1b/2a trial for diabetic macular edema in mid-2026.
The big picture
BioAge's Phase 2 trial of BGE-102 targets the growing recognition of inflammation as a key driver of cardiovascular events, positioning the drug as a potential transformative therapy akin to statins. The company's dual focus on cardiovascular risk and retinal diseases underscores its strategy to leverage NLRP3 inhibition across multiple high-value indications. Success in these trials could validate BioAge's approach to targeting the biology of human aging for therapeutic benefits.
What we're watching
- Clinical Efficacy
- Whether BGE-102 can demonstrate significant hsCRP reductions and normalization in the Phase 2 trial, supporting its path to Phase 3.
- Dose Optimization
- How the dose-ranging data will inform the selection of the optimal dose for Phase 3 trials.
- Market Potential
- The pace at which BioAge can expand BGE-102's application beyond cardiovascular risk to other inflammation-driven diseases like diabetic macular edema.
Related topics